Stemline Therapeutics Loss Narrows

(RTTNews) - Stemline Therapeutics Inc (STML), a clinical stage biopharmaceutical company, on Friday reported fourth-quarter net loss of $6.9 million or $0.53 per share compared with a loss of $7.7 million or $0.60 per share last year.

Results were mainly helped by a decrease in research and general expenses, the company said.

The company's grant revenues for the quarter were $121 thousand compared with $71 thousand in the prior year.

Analysts polled by Thomson Reuters estimated the company to report a loss of $0.60 per share on revenues of $140 thousand for the quarter. Analysts' estimates typically exclude special items.

Stemline Therapeutics is engaged in the development of novel drugs targeting cancer stem cells and tumor bulk.